Jacobson Pharma Announces FY2025 Interim Results

Jacobson Pharma Announces FY2025 Interim Results

KEY HIGHLIGHTS- First-half revenue up by 13.3% to HK$810.0 million- Profit from continuing operations increased by 44.2% to HK$140.3 million- Net gearing ratio significantly down to 5.6% from 12.2%- Interim Dividend of HK3.5 cents per share, up by 40.0% year-on-year- Continued enrichment of pipeline through R&D and strategic in-licensing- Enhanced production capacity and leverage boost operational efficiencyHONG KONG…
Read More

Zaļā Josta - Reklāma